Product Images Clopidogrel

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Clopidogrel NDC 68071-4138 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

pdp - 68071 4138 03 T70

pdp - 68071 4138 03 T70

figure-03a.jpg - figure 03a

figure-03a.jpg - figure 03a

figure-03b.jpg - figure 03b

figure-03b.jpg - figure 03b

figure-06.jpg - figure 06

figure-06.jpg - figure 06

This text contains the results of a clinical trial that evaluated the effectiveness of Clopidogrel compared to Placebo, in patients with Acute Coronary Syndrome. The trial included different subgroups based on gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given. It reports the number of patients in each subgroup, the percentage of patients who favored Clopidogrel, and the odds ratio. It also lists confidence intervals for the overall results.*

figure-08.jpg - figure 08

figure-08.jpg - figure 08

This text appears to be a medical study analyzing the effects of the drugs Clopidogrel and Aspirin on patients with qualifying conditions such as stroke, MI, and PAD. The study reports the number of patients favoring each drug and provides hazard ratios for the years 2006 to 2013.*

Structural formula for clopidogrel bisulfate - image 01

Structural formula for clopidogrel bisulfate - image 01

Figure 1 - image 02

Figure 1 - image 02

Figure 2 - image 03

Figure 2 - image 03

This is a table showing the Cumulative Event Rate of Cardiovascular Death, Myocardial Infarction, and Stroke for a placebo (with aspirin) and Clopdogrel (with aspirin) over several months. Other standard therapies were also used. The P-value is 0.000008. The text also includes some numbers that are likely errors.*

Figure 4 - image 05

Figure 4 - image 05

The text appears to be a table that shows the number of deaths before the first discharge in a study comparing the effectiveness of a placebo versus Clopidogrel. The table shows that out of the total participants, 1845 (3.1%) died with the placebo group and 1726 (7.5%) died in the Clopidogrel group. The table also shows a 7% proportional risk reduction with Clopidogrel in comparison to the placebo, with a p-value of 0.03. The last row of the table shows the timeframe of the study, which was up to 28 days after randomization.*

Figure 5 - image 06

Figure 5 - image 06

This is a statistical data comparison between Placebo and Clopidogrel drugs in terms of their efficacy in reducing death rate, reinfarction, or stroke before the first discharge, measured over a period of 28 days since randomization. The data shows that Clopidogrel has a lower event rate (9.2%) than Placebo (10.1%) and has a 9.7% proportional risk reduction with a p-value of 0.002.*

Figure 8 - image 09

Figure 8 - image 09

This is a chart showing the cumulative event rate for fatal or non-fatal vascular events between the medications Aspirin and Clopidogrel. It shows a significant difference at a p-value of 0.045 over several months of follow-up.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.